Author: webmaster

PassPort Technologies, Inc. (“PPTI”) and IP Gaia, Inc. (“IPG”) have entered into a business commissioning agreement (the “Agreement”) regarding business development activities aimed at partnerships with third parties for PPTI’s platform technology and development pipeline. Through this Agreement, PPTI will be able to leverage IPG’s network for business development activities. Mr. Tomoyuki Fujisawa, the President and CEO of PPTI, stated, “IPG’s extensive network with numerous global pharmaceutical companies is the ultimate business development capability, and it is like a dream function for venture companies like ours. Through the partnership with IPG, we are confident that we can timely deliver our innovative pharmaceuticals and new technologies to partner companies.” Yasunori Yamaguchi, …

Continue reading “IP Gaia and PassPort Technologies Announce the Partnership Agreement”

IPGaia, Inc., (“IPG”) has already concluded a comprehensive business alliance agreement with NanoCarrier Co., Ltd.(“NanoCarrier”) to assume NanoCarrier’s business development function (effective date: March 14, 2023). In order to further strengthen the alliance between the two companies, IPG hereby announces that it has decided to acquire NanoCarrier’s stock acquisition rights through a third-party allotment. Yasunori Yamaguchi, IPG President and CEO, said, “Through this comprehensive business alliance with NanoCarrier since March, IP Gaia is proud to be able to enhance its corporate value as a partner in all business development activities through leveraging IPG’s network, IPG’s established mechanism to capture projects that have been suspended by pharmaceutical companies for strategic reasons …

Continue reading “Notice of Capital and Business Alliance with NanoCarrier Co., Ltd.”

IPGaia, Inc., (“IPG”) and University of California San Diego (“UC San Diego”), based in La Jolla, California, USA, have entered into a Master Collaborative Research and Development Agreement (“this agreement”) dated July 1st, 2022. This agreement establishes a formal framework for the incorporation of promising drug target leads from UC San Diego into IPG’s drug discovery platform.   Following UC San Diego’s strong history of partnering with industry to advance drug discovery, the program enables UC San Diego to propose drug targets to IPG for identification and development of lead compounds or modalities with the goal of licensing clinical development candidates to pharmaceutical companies. For patients, personalized medicine holds great …

Continue reading “IPGaia, Inc. and UC San Diego Announce Master Collaborative Research and Development Agreement”